YF087 not checked

InventisBio Co., Ltd

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Dosage form: Tablet • Administration route: Oral, once a day”In the company’s words, NCT07809607 on ClinicalTrials.gov
Tested for
Advanced Solid Tumor Cancer
Main trialPhase 1
“This is an open-label, multicenter clinical study to evaluate the safety, tolerability, and pharmacokinetics of YF087 in subjects with Microsatellite Instability-High (MSI-H) or Mismatch Repair-Deficient (dMMR) advanced solid tumors.”In the company’s words, NCT07809607 on ClinicalTrials.gov

Other drugs for Advanced Solid Tumor Cancer

All 2440 drugs for Advanced Solid Tumor Cancer

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Not yet recruiting 30 Sep 2028 A Study to Evaluate YF087 in Subjects With MSI-H or dMMR Advanced Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow YF087

Following is part of Solo: you see every change to YF087 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in